Novo Nordisk A/S - ESG Rating & Company Profile powered by AI
The webpage is a free E,S&G analysis covering Novo Nordisk A/S. Other companies in the rating industry group for Novo Nordisk A/S are displayed. Jump to the end of the page for potential risks for Novo Nordisk A/S based on industry, location and marketcap.
Novo Nordisk A/S in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.3; made up of an environmental score of 4.0, social score of 8.0 and governance score of 6.9.
6.3
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 402 | United Laboratories International Holdings Ltd | 6.4 | High |
| 402 | Zenabis Global Inc | 6.4 | High |
| 427 | Novo Nordisk A/S | 6.3 | High |
| 427 | Calliditas Therapeutics AB | 6.3 | High |
| 427 | Carna Biosciences Inc | 6.3 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Novo Nordisk A/S have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Novo Nordisk A/S disclose current and historical energy intensity?
Sign up for free to unlockDoes Novo Nordisk A/S report the average age of the workforce?
Sign up for free to unlockDoes Novo Nordisk A/S reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Novo Nordisk A/S disclose its ethnicity pay gap?
Sign up for free to unlockDoes Novo Nordisk A/S disclose cybersecurity risks?
Sign up for free to unlockDoes Novo Nordisk A/S offer flexible work?
Sign up for free to unlockDoes Novo Nordisk A/S have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Novo Nordisk A/S disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Novo Nordisk A/S conduct supply chain audits?
Sign up for free to unlockDoes Novo Nordisk A/S disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Novo Nordisk A/S conduct 360 degree staff reviews?
Sign up for free to unlockDoes Novo Nordisk A/S disclose the individual responsible for D&I?
Sign up for free to unlockDoes Novo Nordisk A/S disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Novo Nordisk A/S disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Novo Nordisk A/S disclose water use targets?
Sign up for free to unlockDoes Novo Nordisk A/S have careers partnerships with academic institutions?
Sign up for free to unlockDid Novo Nordisk A/S have a product recall in the last two years?
Sign up for free to unlockDoes Novo Nordisk A/S disclose incidents of discrimination?
Sign up for free to unlockDoes Novo Nordisk A/S allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Novo Nordisk A/S issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Novo Nordisk A/S disclose parental leave metrics?
Sign up for free to unlockDoes Novo Nordisk A/S disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Novo Nordisk A/S disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Novo Nordisk A/S disclose the pay ratio of women to men?
Sign up for free to unlockDoes Novo Nordisk A/S support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Novo Nordisk A/S disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Novo Nordisk A/S reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Novo Nordisk A/S involved in embryonic stem cell research?
Sign up for free to unlockDoes Novo Nordisk A/S disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Novo Nordisk A/S disclose its waste policy?
Sign up for free to unlockDoes Novo Nordisk A/S report according to TCFD requirements?
Sign up for free to unlockDoes Novo Nordisk A/S disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Novo Nordisk A/S disclose energy use targets?
Sign up for free to unlockDoes Novo Nordisk A/S disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Novo Nordisk A/S have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Novo Nordisk A/S
These potential risks are based on the size, segment and geographies of the company.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.